Globally, 328 million people are infected with hepatitis B or hepatitis C virus.

Hepatitis B and C cause 1.3 million deaths per year including mortality from liver cancer, the fourth leading cause of cancer deaths globally.

Highly effective interventions are available to prevent transmission, diagnose infection, and treat hepatitis B and cure hepatitis C.

Only 9% of HBV-infected people and 20% of HCV-infected people had been tested and diagnosed. Of those diagnosed with HBV infection, 8% are on treatment, while 7% of those diagnosed with HCV infection have started treatment.

Without elimination efforts, hepatitis B and C deaths will surpass deaths from HIV, TB and malaria combined by 2040.

By reaching the global targets of a 90% reduction in new infections and 65% reduction in mortality, the elimination of viral hepatitis as a public health threat by 2030 will prevent 71 million deaths.

Hepatitis B vaccine is preventing approximately 4.5 million infections per year in children. However, less than half of all newborns receive a timely dose of hepatitis B vaccine.

COALITION STRATEGIC OBJECTIVES

The Coalition for Global Hepatitis Elimination is working to:

- eliminate hepatitis B and C by engaging partners in a community of practice;
- build a trusted evidence base, HEPEXPERT, to guide program development;
- provide technical assistance to programs to overcome barriers in implementation and evaluation;
- conduct operational research to improve effectiveness;
- support global advocacy and community mobilization.

With CHGE, partners have access to credible data to guide program planning and build a case for investment, ongoing technical assistance, and an active community of practice to share lessons learned. Please visit the CGHE website at www.globalhep.org.

WHO IS JOINING

Implementing programs - governments, NGO’s and others currently delivering the interventions that accelerate progress toward goals for HBV and HCV elimination.

Technical partners - organizations providing assistance to hepatitis programs, or working with target populations.

Funding partners - industry, philanthropy, government and others who can provide resources to support Coalition operations.

Nations are in various stages of planning and implementing programs to eliminate HBV and HCV. Public health and clinical data are often not available to guide program development or build a case for investment. Many programs operate in isolation when they could benefit from lessons learned from efforts in their region or across the globe.